medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-5-7-14medalphabet-2583Research ArticleСтатьиКлинико-эпидемиологические характеристики нейроэндокринных опухолей ЖКТ на основе одноцентрового регистраClinical and epidemiological features of neuroendocrine tumors on basis of single-centre registryhttps://orcid.org/0000-0001-7111-1507АндросоваА. В.AndrosovaA. V.

Андросова Александра Валерьевна, аспирант, врач-онколог отделения противоопухолевой лекарственной терапии № 10

Санкт-Петербург

Androsova Aleksandra V., post-graduate student, medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10

 

alexa.androsova.1711@mail.ruhttps://orcid.org/0000-0003-4447-9458ОрловаР. В.OrlovaR. V.

Орлова Рашида Вахидовна, д. м. н., проф., зав. кафедрой онкологии, гл. специалист по клинической онкологии

Санкт-Петербург

SPIN: 3480–2098

Author ID: 401170

Orlova Rashida V., DM Sci. (habil.), head of Chair for Oncology, chief specialist in Clinical Oncology

Saint Petersburg

SPIN: 3480–2098.

Author ID: 40117

orlova_rashida@mail.ruhttps://orcid.org/0000-0003-0211-9809ИвановаА. К.IvanovaA. K.

Иванова Анастасия Константиновна, врач-онколог отделения противоопухолевой лекарственной терапии № 11

Санкт-Петербург

Ivanova Anastasia K., medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 11

Saint Petersburg

oncolog.ivanova@yandex.ruhttps://orcid.org/0000-0003-0402-6067БелякН. П.BelyakN. P.

Беляк Наталья Петровна, к. м. н., ассистент кафедры онкологии, зав. отделением противоопухолевой лекарственной терапии № 10

Санкт-Петербург

SPIN: 2937–4858

Author ID: 778562

Belyak Natalia P., PhD Med, associate professor at Dept of Oncology, head of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10

Saint Petersburg

SPIN: 2937–4858

Author ID: 778562

drnpb@mail.ruhttps://orcid.org/0000-0003-2221-4088КутуковаС. И.KutukovaS. I.

Кутукова Светлана Игоревна, к. м. н., доцент кафедры стоматологии хирургической и челюстно-лицевой хирургии, врач-онколог отделения противоопухолевой лекарственной терапии № 10

Санкт-Петербург

SPIN: 6735–6556

Author ID: 698363

Kutukova Svetlana I., PhD Med, associate professor at Dept of Surgical and Maxillofacial Surgery Dentistry, medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10

Saint Petersburg

SPIN: 6735–6556

Author ID: 698363

dr.s.kutukova@gmail.comhttps://orcid.org/0000-0002-9628-7098КалединаЕ. А.KaledinaE. A.

Каледина Екатерина Александровна, врач-онколог отделения противоопухолевой лекарственной терапии № 10

Санкт-Петербург

SPIN: 8925–3320

Author ID: 1020115

Kaledina Ekaterina A., medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10

Saint Petersburg

SPIN: 8925–3320

Author ID: 1020115

kate199595@mail.ruФГБОУ ВО «Санкт-Петербургский государственный университет»; СПб ГБУЗ «Городской клинический онкологический диспансер»РоссияSaint Petersburg State University; City Clinical Oncology CentreRussian FederationСПб ГБУЗ «Городской клинический онкологический диспансер»РоссияCity Clinical Oncology CentreRussian FederationСПб ГБУЗ «Городской клинический онкологический диспансер»; 3ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова»РоссияCity Clinical Oncology Centre; First Saint Petersburg State Medical University n. a. I. P. PavlovRussian Federation20223004202215Диагностика и онкотерапия (1)714Copyright © Андросова А.В., Орлова Р.В., Иванова А.К., Беляк Н.П., Кутукова С.И., Каледина Е.А., 20222022Андросова А.В., Орлова Р.В., Иванова А.К., Беляк Н.П., Кутукова С.И., Каледина Е.А.Androsova A.V., Orlova R.V., Ivanova A.K., Belyak N.P., Kutukova S.I., Kaledina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2583

Нейроэндокринные опухоли представляют собой гетерогенную группу злокачественных новообразований. Алгоритм назначения того или иного вида лечения, в том числе системного, зависит от степени дифференцировки и распространенности опухоли на основании классификации ВОЗ (2010) и рекомендаций Европейского общества по изучению нейроэндокринных опухолей (НЭО) (ENETS, 2011). Данная нозология является относительно редкой (заболеваемость – от 2 до 5 случаев на 100 тысяч человек). Однако за последние 30 лет отмечается рост числа заболеваний НЭО на 720 %, согласно данным регистра США SEER (Surveillance, Epidemiology, and End Results). В данной статье представлены результаты анализа клинико-эпидемиологических характеристик нейроэндокринных опухолей ЖКТ у пациентов, получавших лечение в СПб ГБУЗ «ГКОД».

Neuroendocrine tumors (NET) are fairly heterogenous malignant tumors. The algorithm of choosing a particular type of treatment, including systemic therapy, depends on the degree of differentiation and tumor burden based on the WHO classification (2010) and the guidelines of the European Neuroendocrine Tumor Society (ENETS, 2011). This nosology is relatively rare (the incidence is 2 to 5 per 100 thousand population).

However, over the past 30 years, there has been an increase in the number of NET diseases by 720 % according to the US SEER (Surveillance, Epidemiology, and End Results) register. This article presents the results of the analysis of the clinical and epidemiological characteristics of neuroendocrine gastrointestinal tumors in patients treated in the St. Petersburg City Clinical Oncology Centre.

нейроэндокринная опухольнейроэндокринный ракнейроэндокринные опухолианалоги соматостатинарегистрneuroendocrine tumorneuroendocrine cancerneuroendocrine tumorssomatostatin analogsregistryReferencesYao J. C., Hassan M., Phan A., Dagohoy C. et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008. 26 (18). Р: 3063–3072. DOI: 10.1200/JCO.2007.15.4377.Yao J. C., Hassan M., Phan A., Dagohoy C. et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008. 26 (18). Р: 3063–3072. DOI: 10.1200/JCO.2007.15.4377.Modlin I. M., Moss S. F., Chang D. C. et al. Priorities for improving the management of gastroenteropancreatic neruoendocrine tumors. J. Natl. Cancer Inst. 2008. 100 (18). Р: 1282–1289. DOI: 10.1093/jnci/djn275.Modlin I. M., Moss S. F., Chang D. C. et al. Priorities for improving the management of gastroenteropancreatic neruoendocrine tumors. J. Natl. Cancer Inst. 2008. 100 (18). Р: 1282–1289. DOI: 10.1093/jnci/djn275.Oberg K., Modlin I. Carcinoid Tumors – Current Considerations in a Century of Advances in Neuriendocrine Tumor. In: Biology and Treatment. 2007. P: 40–53.Oberg K., Modlin I. Carcinoid Tumors – Current Considerations in a Century of Advances in Neuriendocrine Tumor. In: Biology and Treatment. 2007. P: 40–53.Rinke A., Wittenberg M., Schade-Brittinger C., Aminossadati B., Ronicke E., Gress T. M. (PROMID Study Group). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017. 104 (1). P: 26–32. DOI: 10.1159/000443612.Rinke A., Wittenberg M., Schade-Brittinger C., Aminossadati B., Ronicke E., Gress T. M. (PROMID Study Group). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017. 104 (1). P: 26–32. DOI: 10.1159/000443612.Rinke A., Muller H. H., Schade-Brittinger C., Klose K. J., Barth P., Wied M. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009. 27 (28). P: 4656–4663.Rinke A., Muller H. H., Schade-Brittinger C., Klose K. J., Barth P., Wied M. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009. 27 (28). P: 4656–4663.Lee A., Chan D. L., Wong M. H., Li B. T., Lumba S., Clarke S. J. et al. Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology. 2017. 104 (3). P. 209–222. DOI: 10.1159/000446115.Lee A., Chan D. L., Wong M. H., Li B. T., Lumba S., Clarke S. J. et al. Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology. 2017. 104 (3). P. 209–222. DOI: 10.1159/000446115.Öberg K. lnterferon-α versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours. Digestion. 1996. 57 (Suppl. 1). P. 81–83. https://doi.org/10.1159/000201403Öberg K. lnterferon-α versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours. Digestion. 1996. 57 (Suppl. 1). P. 81–83. https://doi.org/10.1159/000201403Kölby L., Persson G., Franzen S., Ahrén B. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. Journal of British Surgery. 2003. 90 (6). P. 687–693. DOI: 10.1002/bjs.4149.Kölby L., Persson G., Franzen S., Ahrén B. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. Journal of British Surgery. 2003. 90 (6). P. 687–693. DOI: 10.1002/bjs.4149.Fazio N., de Braud F., Delle Fave G., Oberg K. Interferon- and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology. 2006. 18 (1). P. 13–19. DOI: 10.1093/annonc/mdl144.Fazio N., de Braud F., Delle Fave G., Oberg K. Interferon- and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology. 2006. 18 (1). P. 13–19. DOI: 10.1093/annonc/mdl144.Raymond E., Dahan L., Raoul J. L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 501–513. DOI: 10.1056/NEJMoa1003825.Raymond E., Dahan L., Raoul J. L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 501–513. DOI: 10.1056/NEJMoa1003825.Capdevila J., Sevilla I., Alonso V., Aparicio L. A., Fonseca P. J., Grande E. et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumors in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015. 15 (495) P. 1–11. DOI: 10.1186/s12885–015–1512–6.Capdevila J., Sevilla I., Alonso V., Aparicio L. A., Fonseca P. J., Grande E. et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumors in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015. 15 (495) P. 1–11. DOI: 10.1186/s12885–015–1512–6.Bajetta E., Catena L., Fazio N., Pusceddu S., Biondani P., Blanco G. et al. Everolimus in combination with octreotide long-acting repeatable in a firstline setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 2014. 120 (16). P. 2457–2463. DOI: 10.1002/cncr.287 26.Bajetta E., Catena L., Fazio N., Pusceddu S., Biondani P., Blanco G. et al. Everolimus in combination with octreotide long-acting repeatable in a firstline setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 2014. 120 (16). P. 2457–2463. DOI: 10.1002/cncr.287 26.Yao J. C., Shah M. H., Ito T. et al. RAD 001 in Advanced neuroendocrine Tumors, 3 Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 514–23. DOI: 10.1056/NEJMoa1009290.Yao J. C., Shah M. H., Ito T. et al. RAD 001 in Advanced neuroendocrine Tumors, 3 Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011. 364 (6). P. 514–23. DOI: 10.1056/NEJMoa1009290.Panzuto F., Rinzivillo M., Fazio N. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014. 19 (9). P. 966–974. DOI: 10.1634/theoncologist.2014–0037.Panzuto F., Rinzivillo M., Fazio N. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014. 19 (9). P. 966–974. DOI: 10.1634/theoncologist.2014–0037.Kamp K., Gumz B., Feelders R. A. et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotate. Endocr Relat Cancer. 2013. 20 (6). P. 825–831. DOI: 10.1530/ERC-13–0254.Kamp K., Gumz B., Feelders R. A. et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotate. Endocr Relat Cancer. 2013. 20 (6). P. 825–831. DOI: 10.1530/ ERC-13–0254.Орел Н. Ф., Артамонова Е. В., Горбунова В. А., Делекторская В. В., Емельянова Г. С., Любимова Н. В. и соавт. Практические рекомендации по лекарственному лечению нейроэндокринных опухолей желудочно-кишечного тракта, поджелудочной железы и других локализаций. Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. 10 (3s2): 524–537. DOI: 10.18027/2224–5057–2020–10–3s2–30.Orel N. F., Artamonova E. V., Gorbunova V. A., Delektorskaya V. V., Emel’yanova G.S., Lubimova N. V. et al. Practical recommendations for the drug treatment of neuroendocrine tumors of the gastrointestinal tract, pancreas and other localizations (in English). Malignant tumors: Practi- cal recommendations RUSSCO. 2020; 10 (3s2): 524–537. DOI: 10.18027/2224–5057–2020–10–3s2–30.

The authors declare that there are no conflicts of interest present.